Vidhance (VIDH) Q1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2025 earnings summary
5 Jun, 2025Executive summary
Net sales for Q1 2025 were SEK 4.8 million, down from SEK 8.1 million year-over-year.
EBITDA for the quarter was SEK -6.6 million, compared to SEK -3.4 million in Q1 2024.
Result after tax was SEK -8.7 million, or SEK -1.89 per share, versus SEK -5.9 million and SEK -1.29 per share last year.
No externally reported significant events during the quarter; CEO Nils Hulth announced resignation post-quarter, with Johan Bolin appointed as successor.
Dividend proposal for 2024 was withdrawn due to market uncertainty and potential tariffs.
Financial highlights
Net sales declined 41% year-over-year to SEK 4.8 million.
EBITDA margin deteriorated, with EBITDA at SEK -6.6 million (Q1 2024: SEK -3.4 million).
Result after financial items was SEK -8.7 million (Q1 2024: SEK -5.9 million).
Cash flow after investments improved to SEK -4.1 million from SEK -7.9 million year-over-year.
Cash and cash equivalents at period end were SEK 45.5 million, down from SEK 57.9 million a year earlier.
Outlook and guidance
Board targets at least SEK 60 million in net sales and a minimum 15% EBITDA margin for full-year 2026.
Ongoing focus on product development, especially AI-driven video solutions and telemedicine.
Market uncertainty due to US-China trade tensions and potential tariffs may delay strategic agreements.
Latest events from Vidhance
- Revenue fell and losses deepened, but strategic shifts aim for future growth.VIDH
Q4 202525 Feb 2026 - Revenue fell and losses persisted, but strategic shifts and cost cuts are underway.VIDH
Q3 202521 Nov 2025 - Revenue and profit fell amid market headwinds; 2026 targets withdrawn, new CEO appointed.VIDH
Q2 202520 Aug 2025 - Revenue and earnings fell in Q3 2024, but strategic AI investments and new markets drive future growth.VIDH
Q3 202413 Jun 2025 - Q2 sales dropped 28% but EBITDA improved; strong cash reserves support ongoing AI investments.VIDH
Q2 202413 Jun 2025 - Net sales fell but EBITDA improved, with a dividend proposed and new telemedicine initiatives launched.VIDH
Q4 20245 Jun 2025